1557336559875129345

Gamida Cell announced the first patient dosed in Phase 1/2 study of #NAMenabled NK cell therapy candidate #GDA201 for treatment of patients with #follicularlymphoma and #diffuselargeBcelllymphoma.

https://t.co/uLC7RDPAGq

#Committedtocures
#NKCellTherapy
#Lymphoma
#LRF https://t.co/84J6INUdB4

Send us a message